

Supplementary Table 1. Estimated hazard ratios (HRs) of recurrence or death and 95% confidence intervals (CIs) from multivariable models for disease-free survival in patients with hormone receptor–positive and HER2-negative or unknown disease*

Covariate	Model 1		Model 2		Model 3		Model 4	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Age at diagnosis: <50 vs ≥50 y	0.97 (0.83 to 1.14)	.756	1.02 (0.86 to 1.19)	.850	0.99 (0.84 to 1.17)	.909	1.00 (0.85 to 1.17)	.960
Positive nodes: 1–3 vs 0	1.44 (0.99 to 2.11)	.056	1.44 (0.99 to 2.10)	.079	1.44 (0.99 to 2.10)	.057	1.46 (1.00 to 2.13)	.050
Positive nodes: ≥4 vs 0	2.85 (1.96 to 4.14)	<.001	2.78 (1.91 to 4.04)	<.001	2.81 (1.93 to 4.08)	<.001	2.83 (1.95 to 4.12)	<.001
Tumor size: >2 vs ≤ 2 cm	1.62 (1.35 to 1.94)	<.001	1.61 (1.34 to 1.93)	<.001	1.61 (1.34 to 1.92)	<.001	1.62 (1.35 to 1.94)	<.001
Breast-sparing surgery vs mastectomy	1.04 (0.88 to 1.24)	.639	1.04 (0.88 to 1.24)	.639	1.05 (0.88 to 1.25)	.584	1.05 (0.88 to 1.25)	.588
Tam alone vs AI ±Tam	1.07 (0.90 to 1.27)	.426	1.08 (0.91 to 1.28)	.361	1.08 (0.91 to 1.28)	.369	1.08 (0.91 to 1.28)	.356
No endocrine therapy or unknown vs AI ±Tam	1.92 (1.46 to 2.51)	<.001	1.93 (1.47 to 2.53)	<.001	1.91 (1.45 to 2.50)	<.001	1.93 (1.47 to 2.53)	<.001
Black vs nonblack	1.66 (1.25 to 2.21)	<.001	NA	NA	1.58 (1.18 to 2.11)	.002	BMI ≥30 kg/m ² : 1.19 (0.80 to 1.77)	.382
							BMI <30 kg/m ² : 2.38 (1.57 to 3.60)	<.001
BMI: ≥30 vs <30 kg/m ²	NA	NA	1.27 (1.08 to 1.49)	.003	1.22 (1.04 to 1.44)	.014	NA	NA

*All *P* values are two-sided. Tam = tamoxifen; AI = aromatase inhibitor; BMI = body mass index; NA = not applicable.

Supplementary Table 2. Estimated hazard ratios (HRs) of death and 95% confidence intervals (CIs) from multivariable models for overall survival in patients with hormone receptor–positive and HER2-negative or unknown disease*

Covariate	Model 1		Model 2		Model 3		Model 4	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Age at diagnosis: <50 vs ≥50 y	0.80 (0.66 to 0.98)	.031	0.84 (0.69 to 1.03)	.091	0.82 (0.67 to 1.01)	.057	0.83 (0.68 to 1.01)	.066
Positive nodes: 1–3 vs 0	1.64 (0.99 to 2.72)	.053	1.65 (1.00 to 2.73)	.051	1.65 (1.00 to 2.74)	.050	1.68 (1.01 to 2.78)	.044
Positive nodes: ≥4 vs 0	3.38 (2.06 to 5.56)	<.001	3.27 (1.99 to 5.38)	<.001	3.30 (2.01 to 5.44)	<.001	3.34 (2.03 to 5.50)	<.001
Tumor size: >2 vs ≤2 cm	1.76 (1.41 to 2.21)	<.001	1.74 (1.39 to 2.18)	<.001	1.74 (1.39 to 2.18)	<.001	1.76 (1.40 to 2.20)	<.001
Breast-sparing surgery vs mastectomy	1.19 (0.96 to 1.48)	.114	1.20 (0.96 to 1.50)	.101	1.21 (0.97 to 1.51)	.091	1.21 (0.97 to 1.51)	.091
Tam alone vs AI ±Tam	1.36 (1.11 to 1.66)	.004	1.36 (1.11 to 1.68)	.003	1.37 (1.11 to 1.68)	.003	1.37 (1.12 to 1.69)	.003
No endocrine therapy or unknown vs AI ±Tam	2.39 (1.74 to 3.27)	<.001	2.37 (1.72 to 3.26)	<.001	2.35 (1.71 to 3.23)	<.001	2.39 (1.74 to 3.29)	<.001
Black vs nonblack	1.64 (1.15 to 2.33)	.006	NA	NA	1.51 (1.05 to 2.16)	.025	BMI ≥30 kg/m ² :	.800
							BMI <30 kg/m ² :	<.001
BMI: ≥30 vs <30 kg/m ²	NA	NA	1.40 (1.15 to 1.69)	<.001	1.35 (1.11 to 1.64)	.003	NA	NA

*All *P* values are two-sided. Tam = tamoxifen; AI = aromatase inhibitor; BMI = body mass index; NA = not applicable.

Supplementary Table 3. Estimated hazard ratios (HRs) of death from breast cancer and 95% confidence intervals (CIs) from multivariable models for breast cancer –specific survival in patients with hormone receptor–positive and HER2-negative or unknown disease*

Covariate	Model 1		Model 2		Model 3		Model 4	
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age at diagnosis: <50 vs ≥50 y	1.04 (0.83 to 1.31)	.734	1.10 (0.87 to 1.38)	.435	1.06 (0.85 to 1.34)	.595	1.07 (0.85 to 1.35)	.550
Positive nodes: 1–3 vs 0	2.28 (1.15 to 4.51)	.018	2.29 (1.16 to 4.52)	.018	2.29 (1.16 to 4.52)	.018	2.32 (1.17 to 4.60)	.016
Positive nodes: ≥4 vs 0	5.09 (2.59 to 9.98)	<.001	4.88 (2.49 to 9.59)	<.001	4.94 (2.52 to 9.70)	<.001	5.00 (2.55 to 9.82)	<.001
Tumor size: >2 vs ≤2 cm	1.88 (1.44 to 2.45)	<.001	1.86 (1.42 to 2.43)	<.001	1.85 (1.42 to 2.42)	<.001	1.87 (1.43 to 2.45)	<.001
Breast-sparing surgery vs mastectomy	1.26 (0.97 to 1.63)	.080	1.28 (0.98 to 1.66)	.066	1.29 (0.99 to 1.67)	.059	1.29 (0.99 to 1.67)	.060
Tam alone vs AI ±Tam	1.00 (0.79 to 1.28)	.980	1.01 (0.79 to 1.29)	.945	1.01 (0.79 to 1.29)	.937	1.01 (0.79 to 1.29)	.913
No endocrine therapy or unknown vs AI ±Tam	1.80 (1.23 to 2.65)	.003	1.84 (1.25 to 2.69)	.002	1.82 (1.24 to 2.67)	.002	1.86 (1.26 to 2.73)	.002
Black vs nonblack	1.81 (1.23 to 2.68)	.003	NA	NA	1.65 (1.11 to 2.46)	.013	BMI ≥30 kg/m ² :	.562
							BMI <30 kg/m ² :	<.001
BMI: ≥30 vs <30 kg/m ²	NA		1.45 (1.16 to 1.82)	.001	1.39 (1.11 to 1.75)	.005	NA	NA

*All P values are two-sided. Tam = tamoxifen; AI = aromatase inhibitor; BMI = body mass index; NA = not applicable.

Supplementary Table 4. Most common grade 3 and 4 toxicity during chemotherapy*

Treatment group	Black patients, %	Nonblack patients, %	<i>P</i> †
AC Chemotherapy			
Neutropenia (grade 4 only)	31	38	.017
Febrile neutropenia	8	6	.18
Infection	7	10	.14
Cardiac toxicity	0.3	0.1	.30
Taxane therapy			
Neutropenia (grade 4 only)	13	14	.63
Febrile neutropenia	5	4	.49
Infection	6	6	.63
Myalgia	5	4	.32
Arthralgia	4	4	.77
Neuropathy			
Grade 3 or 4	7	5	.11
Grade 2, 3, or 4	25	19	.020
During AC and taxane therapy			
Hypertension (any grade)	9.8	1.5	.16

*AC = doxorubicin and cyclophosphamide.

† *P* values are two-sided and calculated from the Fisher exact test.